These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 11041567)
1. Prolonged survival after intensive therapy and purged ABMT in patients with multiple myeloma. Reece DE; Brockington DA; Phillips GL; Barnett MJ; Klingemann HG; Nantel SH; Sutherland HJ; Shepherd JD Bone Marrow Transplant; 2000 Sep; 26(6):621-6. PubMed ID: 11041567 [TBL] [Abstract][Full Text] [Related]
2. Treatment of multiple myeloma with intensive chemotherapy followed by autologous BMT using marrow purged with 4-hydroperoxycyclophosphamide. Reece DE; Barnett MJ; Connors JM; Klingemann HG; O'Reilly SE; Shepherd JD; Sutherland HJ; Phillips GL Bone Marrow Transplant; 1993 Feb; 11(2):139-46. PubMed ID: 8435663 [TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J; Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267 [TBL] [Abstract][Full Text] [Related]
4. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276 [TBL] [Abstract][Full Text] [Related]
5. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH; Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634 [TBL] [Abstract][Full Text] [Related]
6. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol]. Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962 [TBL] [Abstract][Full Text] [Related]
7. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574 [TBL] [Abstract][Full Text] [Related]
8. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma. Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951 [TBL] [Abstract][Full Text] [Related]
9. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425 [TBL] [Abstract][Full Text] [Related]
10. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253 [TBL] [Abstract][Full Text] [Related]
11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
12. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252 [TBL] [Abstract][Full Text] [Related]
13. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C J BUON; 2007; 12(1):41-4. PubMed ID: 17436400 [TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
15. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. Freedman AS; Neuberg D; Gribben JG; Mauch P; Soiffer RJ; Fisher DC; Anderson KC; Andersen N; Schlossman R; Kroon M; Ritz J; Aster J; Nadler LM J Clin Oncol; 1998 Jan; 16(1):13-8. PubMed ID: 9440717 [TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Gisselbrecht C; Extra JM; Lotz JP; Devaux Y; Janvier M; Peny AM; Guillevin L; Bremond D; Delain M; Herbrecht R; Lepage E; Maraninchi D Bone Marrow Transplant; 1996 Nov; 18(5):857-63. PubMed ID: 8932837 [TBL] [Abstract][Full Text] [Related]
17. [Autologous transplantation of peripheral hematopoietic cells and subsequent maintenance therapy with interferon alpha or interferon alpha and dexamethasone in patients with multiple myeloma--results from the 4W randomized clinical trial of the Czech Myeloma Group]. Krejcí M; Hájek R; Scudla V; Bacovský J; Indrák K; Faber E; Koza V; Schützová M; Kuca B; Sumná E; Franková H; Lehanka F; Gumulec J; Stavarová Y; Rezek Z; Praskac P; Cahová S; Vránová M; Veprek K; Januska J; Kessler P; Pozdĕnová V; Walterová L; Stefánek I; Hausdorf P; Meluzínová I; Novosadová L; Lenícková S; Dusek L; Syobodník A; Králová E; Adam Z; Mayer J; Vorlícek J Vnitr Lek; 2001 Sep; 47 Suppl 1():40-7. PubMed ID: 11693062 [TBL] [Abstract][Full Text] [Related]
18. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306 [TBL] [Abstract][Full Text] [Related]
19. Maintenance treatment with recombinant alpha interferon after autologous bone marrow transplantation for aggressive myeloma in first remission after conventional induction chemotherapy. Attal M; Huguet F; Schlaifer D; Payen C; Lassoued S; Laroche M; Rossi JF; Fournie B; Mazieres B; Pris J Bone Marrow Transplant; 1991 Aug; 8(2):125-8. PubMed ID: 1933053 [TBL] [Abstract][Full Text] [Related]
20. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma. Cogle CR; Moreb JS; Leather HL; Finiewicz KJ; Khan SA; Reddy VS; Wingard JR Am J Hematol; 2003 Jul; 73(3):169-75. PubMed ID: 12827653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]